#1 Clinical Trials Search in Europe

Fadraciclib

Fadraciclib, also known as CYC065, is an innovative drug currently being studied in clinical trials for various types of cancer. This oral medication is a highly selective inhibitor of CDK2 and CDK9, which are important proteins involved in cell growth and division. The ongoing research aims to evaluate the safety, effectiveness, and potential benefits of Fadraciclib in treating different cancers, including leukemia, myelodysplastic syndrome (MDS), solid tumors, and lymphoma.

Table of Contents

What is Fadraciclib?

Fadraciclib, also known as CYC065, is a new drug being developed for the treatment of various types of cancer[1][2]. It is classified as a highly selective, 2nd generation amino-purine inhibitor that targets specific proteins in cancer cells[1]. This means that Fadraciclib is designed to be more precise in its action, potentially leading to better effectiveness and fewer side effects compared to older cancer treatments.

How Does Fadraciclib Work?

Fadraciclib works by inhibiting two important proteins in cancer cells: CDK2 and CDK9[1]. CDK stands for Cyclin-Dependent Kinase, which are enzymes that play crucial roles in cell division and growth. By blocking these proteins, Fadraciclib can potentially slow down or stop the growth of cancer cells[2]. This mechanism of action is particularly interesting because it targets processes that are often overactive in cancer cells, potentially making the treatment more specific to cancer cells while sparing healthy cells.

What Conditions Does Fadraciclib Treat?

Fadraciclib is being studied for the treatment of several types of cancer, including:

  • Leukemia: A cancer of the blood cells[1]
  • Myelodysplastic Syndrome (MDS): A group of disorders where blood cells don’t develop properly[1]
  • Advanced solid tumors: Cancers that form solid masses in organs or tissues[2]
  • Lymphoma: Cancer that begins in cells of the lymph system[2]

It’s important to note that Fadraciclib is primarily being studied in patients who have already tried standard treatments or for whom no standard treatments exist[1][2]. This means it could potentially offer hope to patients who have limited treatment options.

Current Clinical Trials

Fadraciclib is currently being studied in several clinical trials:

  1. A Phase 1/2 study for patients with leukemia or myelodysplastic syndrome[1]
  2. A Phase 1/2 study for patients with advanced solid tumors and lymphoma[2]
  3. A Phase 1 study to understand how the drug is absorbed, metabolized, and excreted in healthy male subjects[3]
  4. A European proof-of-concept trial for pediatric cancers, where Fadraciclib is being tested in combination with other drugs[4]

These trials aim to determine the safe and effective dose of Fadraciclib, understand how it works in the body, and evaluate its effectiveness against various types of cancer.

How is Fadraciclib Administered?

Fadraciclib can be administered in two ways:

  • Orally: As capsules or tablets that patients can take by mouth[1][2]
  • Intravenously (IV): Given directly into the bloodstream through a vein[4]

The exact dosing schedule varies depending on the specific clinical trial and the condition being treated. In some trials, Fadraciclib is given in combination with other cancer drugs to potentially enhance its effectiveness[4].

Potential Side Effects

As Fadraciclib is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring patients for any adverse reactions[1][2]. Common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts, but the specific side effects of Fadraciclib will be better understood as more data from clinical trials becomes available.

Future Research and Potential

Fadraciclib represents a new approach to cancer treatment, targeting specific proteins involved in cancer cell growth. The ongoing clinical trials will help determine its effectiveness and safety profile. If successful, Fadraciclib could potentially offer a new treatment option for patients with various types of cancer, especially those who have not responded to other treatments[1][2].

Researchers are also exploring how Fadraciclib interacts with other cancer treatments and whether combining it with existing therapies could lead to better outcomes for patients[4]. As research continues, we may learn more about which patients are most likely to benefit from this new drug and how it can be best used in cancer treatment.

Aspect Details
Drug Name Fadraciclib (CYC065)
Drug Type Oral CDK2/9 inhibitor
Targeted Conditions Leukemia, Myelodysplastic Syndrome (MDS), Solid Tumors, Lymphoma
Administration Oral capsules or tablets, various dosing schedules
Clinical Trial Phases Phase 1/2
Primary Outcomes Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), Objective Response Rate (ORR)
Secondary Outcomes Pharmacokinetics, Progression-Free Survival, Duration of Response
Combination Therapies Being studied with other drugs like temozolomide, cytarabine, and everolimus

FAQ

  • What is Fadraciclib? Fadraciclib, also known as CYC065, is an oral medication that works by inhibiting two important proteins called CDK2 and CDK9. These proteins are involved in cell growth and division, and by blocking them, Fadraciclib may help slow down or stop cancer cell growth.
  • What types of cancer is Fadraciclib being studied for? Fadraciclib is being investigated for various types of cancer, including leukemia, myelodysplastic syndrome (MDS), solid tumors (such as breast, ovarian, and colorectal cancers), and lymphoma.
  • How is Fadraciclib administered? Fadraciclib is typically administered orally as capsules or tablets. The dosing schedule may vary depending on the specific clinical trial and the type of cancer being treated.
  • What are the potential side effects of Fadraciclib? As Fadraciclib is still in clinical trials, the full range of side effects is not yet known. However, researchers are closely monitoring participants for any adverse reactions. Common side effects of cancer treatments may include fatigue, nausea, and changes in blood cell counts.
  • How can I participate in a clinical trial for Fadraciclib? To participate in a clinical trial for Fadraciclib, you would need to meet specific eligibility criteria. These may include having a particular type of cancer, having tried certain previous treatments, or meeting other health requirements. Speak with your oncologist about whether you might be eligible for any ongoing Fadraciclib trials.

Ongoing Clinical Trials on Fadraciclib

  • Study of Fadraciclib in Adults with Advanced Solid Tumors (Including Breast, Colorectal, Endometrial, Ovarian, Biliary Tract, and Liver Cancer) and Lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • CDK2/9: CDK2 and CDK9 are proteins (cyclin-dependent kinases) that play important roles in cell division and growth. Fadraciclib works by inhibiting these proteins to potentially slow down or stop cancer cell growth.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow does not produce enough healthy blood cells. It is sometimes referred to as 'pre-leukemia.'
  • Leukemia: A type of blood cancer that starts in blood-forming tissue, such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the bloodstream.
  • Solid Tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancerous) or malignant (cancerous).
  • Lymphoma: A type of cancer that begins in cells of the lymph system, which is part of the body's immune system.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Recommended Phase II Dose (RP2D): The dose of a drug determined to be appropriate for further testing in Phase II clinical trials, based on safety and effectiveness data from Phase I trials.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.

References

  1. https://clinicaltrials.gov/study/NCT05168904
  2. https://clinicaltrials.gov/study/NCT04983810
  3. https://clinicaltrials.gov/study/NCT05817890
  4. https://clinicaltrials.eu/trial/study-on-everolimus-and-drug-combination-for-children-with-relapsed-or-refractory-pediatric-cancer/